AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15765114 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 473
Study 15765114 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT with cyclophosphamide during mobilization
Number of subjects: 473
Study 12410054 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing fruit-flavored chewing gum for 10 minutes
Number of subjects: 30
Study 12410054 — intervention group
Group type: EXPERIMENTAL
Intervention: Betel chewing
Number of subjects: 30
Study 10218748 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-verapamil (180 to 480 mg)
Number of subjects: 528
Study 10218748 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS (30 to 120 mg/d)
Number of subjects: 528
Study 7502998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet ownership (dog owners)
Number of subjects: 424
Study 7502998 — intervention group
Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 424
Study 7502998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall social support
Number of subjects: 424
Study 7502998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pet ownership
Number of subjects: 424
Study 31850987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (gastric bypass, banding, or vertical banded gastroplasty)
Number of subjects: 2007
Study 31850987 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (specific types not detailed)
Number of subjects: 2007
Study 31850987 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2007
Study 29733225 — intervention group
Group type: EXPERIMENTAL
Intervention: Right carotid sinus compression for 20 sec
Number of subjects: 64
Study 29733225 — intervention group
Group type: COMPARATOR
Intervention: Placebo technique of placing hands on the radial styloid processes
Number of subjects: 64
Study 28083873 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) course
Number of subjects: 90
Study 28083873 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture-based courses
Number of subjects: 90
Study 25060039 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting Tai Chi
Number of subjects: 59
Study 25060039 — intervention group
Group type: COMPARATOR
Intervention: Mobilizing exercises (Control)
Number of subjects: 59
Study 24093362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy
Number of subjects: 581
Study 24093362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy among non-Hispanic White participants
Number of subjects: 581
Study 24093362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher health literacy among Hispanic/other race participants
Number of subjects: 581
Study 21831504 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training course
Number of subjects: 54
Study 20016176 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF(2) toothpaste + AmF/SnF(2) mouthwash
Number of subjects: 30
Study 20016176 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF(2) toothpaste + tap water rinse
Number of subjects: 30
Study 20016176 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF/SnF(2) toothpaste + no rinse (spit out only)
Number of subjects: 30
Study 17097048 — intervention group
Group type: EXPERIMENTAL
Intervention: Video containing information based on the Self Regulatory Model of health beliefs
Number of subjects: 44
Study 17097048 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 44
Study 15251644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin infusion therapy
Number of subjects: 0
Study 11704175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (mean 3.8 sessions with obstetrician and one with midwife)
Number of subjects: 176
Study 11704175 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (mean 2.0 sessions)
Number of subjects: 176
Study 11704175 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 176
Study 9310537 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nasogastric gavage (CNG)
Number of subjects: 80
Study 9310537 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus gavage (IBG)
Number of subjects: 80
Study 9310537 — intervention group
Group type: EXPERIMENTAL
Intervention: CNG
Number of subjects: 80
Study 9310537 — intervention group
Group type: COMPARATOR
Intervention: IBG
Number of subjects: 80
Study 7514705 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetic acid (all four concentrations)
Number of subjects: 10
Study 7514705 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyl acetate (all four concentrations)
Number of subjects: 10
Study 7514705 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenethyl alcohol (all four concentrations)
Number of subjects: 10
Study 3311285 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical incision
Number of subjects: 115
Study 3311285 — intervention group
Group type: COMPARATOR
Intervention: Circumumbilical incision
Number of subjects: 115
Study 31999297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of treatment with good visual acuity (CTGVA) group
Number of subjects: 625
Study 31999297 — intervention group
Group type: COMPARATOR
Intervention: Other group
Number of subjects: 625
Study 31999297 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGVA group
Number of subjects: 625
Study 31999297 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGVA group (as-needed treatment)
Number of subjects: 625
Study 29476546 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL-assisted MAL-PDT
Number of subjects: 20
Study 29476546 — intervention group
Group type: COMPARATOR
Intervention: Conventional MAL-PDT
Number of subjects: 20
Study 27852241 — intervention group
Group type: EXPERIMENTAL
Intervention: 25° back‐up position
Number of subjects: 781
Study 27852241 — intervention group
Group type: COMPARATOR
Intervention: Standard supine sniffing position
Number of subjects: 781
Study 23743817 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diodes therapy (LEDT)
Number of subjects: 10
Study 23743817 — intervention group
Group type: COMPARATOR
Intervention: Sham application
Number of subjects: 10
Study 22539379 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase (2U daily for 2 days postoperatively)
Number of subjects: 60
Study 22539379 — intervention group
Group type: COMPARATOR
Intervention: Control (no hemocoagulase)
Number of subjects: 60
Study 22539379 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemocoagulase
Number of subjects: 60
Study 22539379 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 19944893 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillomandibular advancement (MMA) surgery
Number of subjects: 50
Study 19944893 — intervention group
Group type: COMPARATOR
Intervention: Autotitrating positive airway pressure (APAP)
Number of subjects: 50
Study 19708820 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-specific therapies
Number of subjects: 0
Study 15850125 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal effort single-leg vertical jumps on the dominant leg
Number of subjects: 25
Study 15850125 — intervention group
Group type: COMPARATOR
Intervention: Maximal effort single-leg vertical jumps on the non-dominant leg
Number of subjects: 25
Study 15850125 — intervention group
Group type: COMPARATOR
Intervention: Comparison of jump height between men and women
Number of subjects: 25
Study 15850125 — intervention group
Group type: COMPARATOR
Intervention: Assessment of thigh length and peak vertical ground reaction force
Number of subjects: 25
Study 15850125 — intervention group
Group type: COMPARATOR
Intervention: Analysis of minimum ankle and hip angles, and vertical ground reaction forces
Number of subjects: 25
Study 12848782 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily
Number of subjects: 15
Study 12848782 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 micro g twice daily
Number of subjects: 15
Study 12848782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10568080 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater impairment in instrumental activities of daily living
Number of subjects: 881
Study 10568080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive disorder
Number of subjects: 881
Study 10568080 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores on the General Health Questionnaire
Number of subjects: 881
Study 10568080 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic disorder
Number of subjects: 881
Study 8739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 100 mg t.i.d.
Number of subjects: 32
Study 8739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg t.i.d.
Number of subjects: 32
Study 8739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 400 mg t.i.d.
Number of subjects: 32
Study 8739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 800 mg t.i.d.
Number of subjects: 32
Study 8739811 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide 100/25 mg (given on days 2 and 7)
Number of subjects: 32
Study 1831059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) 300 mg five times daily
Number of subjects: 193
Study 1831059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 1831059 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 193
Study 6642790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (CD) 15 mg 1 X daily, increased to 20 mg 1 X daily if poor response
Number of subjects: 20
Study 6642790 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (HD) 25 mg 3 X daily, increased to 50 mg 2 X daily if poor response
Number of subjects: 20
Study 6642790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 20
Study 6642790 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (HD)
Number of subjects: 20
Study 6642790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (CD)
Number of subjects: 20
Study 30430372 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU caplets, administered weekly)
Number of subjects: 35
Study 30430372 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered weekly)
Number of subjects: 35
Study 30241565 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calorie high protein diet (HP) with protein as 22-30% total calorie intake for 8 weeks
Number of subjects: 0
Study 30241565 — intervention group
Group type: COMPARATOR
Intervention: Low calorie standard protein diet (SP) with protein as 12-20% total calorie intake for 8 weeks
Number of subjects: 0
Study 30241565 — intervention group
Group type: COMPARATOR
Intervention: Comparison between HP and SP groups
Number of subjects: 0
Study 26702120 — intervention group
Group type: EXPERIMENTAL
Intervention: FruEx (exercise, then fructose condition)
Number of subjects: 8
Study 26702120 — intervention group
Group type: EXPERIMENTAL
Intervention: ExFru (exercise, then fructose condition)
Number of subjects: 8
Study 26702120 — intervention group
Group type: COMPARATOR
Intervention: NoEx (fructose treatment alone with no exercise condition)
Number of subjects: 8
Study 26702120 — intervention group
Group type: EXPERIMENTAL
Intervention: FruEx
Number of subjects: 8
Study 26702120 — intervention group
Group type: EXPERIMENTAL
Intervention: ExFru
Number of subjects: 8
Study 26702120 — intervention group
Group type: COMPARATOR
Intervention: NoEx
Number of subjects: 8
Study 26702120 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 8
Study 23798005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for Living (RFL)
Number of subjects: 1075
Study 22574737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium butyrate (80 mM) enema, twice daily for 3 days
Number of subjects: 80
Study 22574737 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 21117498 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride immediate-release tablet formulations
Number of subjects: 0
Study 21117498 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions for metformin hydrochloride release
Number of subjects: 0
Study 17463382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (fathers participated in the intervention)
Number of subjects: 277
Study 17463382 — intervention group
Group type: COMPARATOR
Intervention: Control group (fathers did not participate in the intervention)
Number of subjects: 277
Study 15277137 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching workshop for residents (two-day workshop)
Number of subjects: 16
Study 15277137 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 11444420 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed calcium carbonate
Number of subjects: 24
Study 11444420 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated calcium carbonate
Number of subjects: 24
Study 11444420 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed calcium citrate
Number of subjects: 24
Study 11444420 — intervention group
Group type: COMPARATOR
Intervention: No-load blank
Number of subjects: 24
Study 9553833 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture at the non-sympathetic, placebo point
Number of subjects: 38
Study 9553833 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture at the sympathetic point
Number of subjects: 38
Study 9553833 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no acupuncture)
Number of subjects: 38
Study 7925171 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma-vinyl GABA, VGB)
Number of subjects: 20
Study 2454027 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg daily for two days, then 20 mg once daily
Number of subjects: 34
Study 2454027 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily for two days, then 375 mg twice daily
Number of subjects: 34
Study 29489734 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal left temporal lobe stimulation
Number of subjects: 38
Study 29489734 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 38
Study 29489734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalic montage (anode over left temporal lobe, cathode over right prefrontal cortex)
Number of subjects: 38
Study 29489734 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracephalic montage (cathode on shoulder)
Number of subjects: 38
Study 28697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Ezetimibe administered in the morning (8:00 am) for 6 weeks and then in the evening for the next 6 weeks
Number of subjects: 200
Study 28697767 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin and Ezetimibe administered in the evening (8:00 pm) for the first 6 weeks and then in the morning for the following 6 weeks
Number of subjects: 200
Study 28697767 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin and Ezetimibe (both administration times)
Number of subjects: 200
Study 26525836 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 92
Study 26525836 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 92
Study 23813584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral paraspinal mapping and testing of 6 muscles on the most symptomatic limb
Number of subjects: 73
Study 21181600 — intervention group
Group type: EXPERIMENTAL
Intervention: Online version of the Weight Management Support Inventory
Number of subjects: 199
Study 21181600 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the Weight Management Support Inventory
Number of subjects: 199
Study 21181600 — intervention group
Group type: EXPERIMENTAL
Intervention: Posting messages on Internet forums several times per day
Number of subjects: 199
Study 21181600 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental support items in the Weight Management Support Inventory
Number of subjects: 199
Study 19762739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (3 times 30 min at 2 vol% interspersed by 30 min of air)
Number of subjects: 0
Study 19762739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation (<1 vol% end-tidal concentration)
Number of subjects: 0
Study 19762739 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0
Study 17174222 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg/d
Number of subjects: 598
Study 17174222 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg/d
Number of subjects: 598
Study 17174222 — intervention group
Group type: COMPARATOR
Intervention: glibenclamide
Number of subjects: 598
Study 15185314 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN‐alpha plus ribavirin (n = 20)
Number of subjects: 40
Study 15185314 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG IFN‐alpha monotherapy (n = 20)
Number of subjects: 40
Study 15185314 — intervention group
Group type: COMPARATOR
Intervention: Untreated subjects (n = 14)
Number of subjects: 40
Study 15185314 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated subjects (both PEG IFN‐alpha plus ribavirin and PEG IFN‐alpha monotherapy)
Number of subjects: 40
Study 15185314 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated subjects with sustained virological responses
Number of subjects: 40
Study 15185314 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated subjects who developed chronic infection
Number of subjects: 40
Study 11471091 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a parental history of myopia
Number of subjects: 153
Study 11471091 — intervention group
Group type: COMPARATOR
Intervention: Children without a parental history of myopia
Number of subjects: 153
Study 9664985 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 15 mg/kg per day
Number of subjects: 33
Study 9664985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7626348 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proatrial natriuretic factor (1-98) concentration
Number of subjects: 64
Study 2571501 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 2571501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 2571501 — intervention group
Group type: COMPARATOR
Intervention: Control group (not on chronic nifedipine therapy)
Number of subjects: 0
Study 321103 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine hydrochloride 0.2 mg
Number of subjects: 40
Study 321103 — intervention group
Group type: EXPERIMENTAL
Intervention: buprenorphine hydrochloride 0.4 mg
Number of subjects: 40
Study 321103 — intervention group
Group type: COMPARATOR
Intervention: morphine sulphate 5 mg
Number of subjects: 40
Study 321103 — intervention group
Group type: COMPARATOR
Intervention: morphine sulphate 10 mg
Number of subjects: 40
Study 31132582 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DESs)
Number of subjects: 10072
Study 28373633 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured writing (n=10; 70% female)
Number of subjects: 22
Study 28373633 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control group (n=12; 67% female)
Number of subjects: 22
Study 26083005 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabipur
Number of subjects: 90
Study 26083005 — intervention group
Group type: EXPERIMENTAL
Intervention: Verorab
Number of subjects: 90
Study 24645908 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing (WGS)
Number of subjects: 200
Study 24645908 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 200
Study 22573933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 200-1200 μg
Number of subjects: 72
Study 22573933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 1-1200 μg
Number of subjects: 72
Study 22573933 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide
Number of subjects: 72
Study 22573933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 19485982 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose peginterferon-alpha-2b (1.5 microg/kg/week) plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A)
Number of subjects: 34
Study 19485982 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B)
Number of subjects: 34
Study 19485982 — intervention group
Group type: COMPARATOR
Intervention: No extended treatment (group C)
Number of subjects: 34
Study 17590184 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of injury mechanisms reported
Number of subjects: 394
Study 17590184 — intervention group
Group type: EXPERIMENTAL
Intervention: Home hazards
Number of subjects: 394
Study 17590184 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of exclusive breastfeeding
Number of subjects: 394
Study 17590184 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal involvement-responsiveness
Number of subjects: 394
Study 17590184 — intervention group
Group type: EXPERIMENTAL
Intervention: Home organization
Number of subjects: 394
Study 17590184 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal paid work
Number of subjects: 394
Study 15362963 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 64
Study 11732026 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oral antibiotics (penicillin VK, 500 mg every 6 hours for 5 days)
Number of subjects: 30
Study 11732026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral placebo, same schedule as group 1)
Number of subjects: 30
Study 9885688 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms sufentanil added to 7.5 mg bupivacaine
Number of subjects: 60
Study 9885688 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms fentanyl added to 7.5 mg bupivacaine
Number of subjects: 60
Study 9885688 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg bupivacaine alone
Number of subjects: 60
Study 8004297 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 800 micrograms by Turbuhaler
Number of subjects: 12